JP2025170244A5 - - Google Patents

Info

Publication number
JP2025170244A5
JP2025170244A5 JP2025123800A JP2025123800A JP2025170244A5 JP 2025170244 A5 JP2025170244 A5 JP 2025170244A5 JP 2025123800 A JP2025123800 A JP 2025123800A JP 2025123800 A JP2025123800 A JP 2025123800A JP 2025170244 A5 JP2025170244 A5 JP 2025170244A5
Authority
JP
Japan
Prior art keywords
cancer
group
alkyl
agents
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025123800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025170244A (ja
Filing date
Publication date
Priority claimed from JP2021574927A external-priority patent/JP7818404B2/ja
Application filed filed Critical
Publication of JP2025170244A publication Critical patent/JP2025170244A/ja
Publication of JP2025170244A5 publication Critical patent/JP2025170244A5/ja
Pending legal-status Critical Current

Links

JP2025123800A 2019-06-20 2025-07-24 Pd-l1疾患の治療のための化合物 Pending JP2025170244A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962864002P 2019-06-20 2019-06-20
US62/864,002 2019-06-20
JP2021574927A JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物
PCT/US2020/038586 WO2020257549A2 (en) 2019-06-20 2020-06-19 Compounds for treatment of pd-l1 diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021574927A Division JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物

Publications (2)

Publication Number Publication Date
JP2025170244A JP2025170244A (ja) 2025-11-18
JP2025170244A5 true JP2025170244A5 (enExample) 2026-02-18

Family

ID=74040685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574927A Active JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物
JP2025123800A Pending JP2025170244A (ja) 2019-06-20 2025-07-24 Pd-l1疾患の治療のための化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021574927A Active JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物

Country Status (13)

Country Link
US (1) US11485708B2 (enExample)
EP (1) EP3986392A4 (enExample)
JP (2) JP7818404B2 (enExample)
KR (1) KR102841588B1 (enExample)
CN (1) CN114072135A (enExample)
AU (1) AU2020294781B2 (enExample)
BR (1) BR112021023750A2 (enExample)
CA (1) CA3139242A1 (enExample)
IL (1) IL288523A (enExample)
MA (1) MA55325A (enExample)
MX (1) MX2021015708A (enExample)
SG (1) SG11202112875UA (enExample)
WO (1) WO2020257549A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2849181T3 (es) 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102841588B1 (ko) * 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2021275118A1 (en) 2020-05-22 2022-12-01 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
WO2022150314A1 (en) * 2021-01-05 2022-07-14 Southern Research Institute Modulators of programmed death-ligand-1
TWI770866B (zh) * 2021-03-10 2022-07-11 國立清華大學 鹵化物材料及包含該鹵化物材料之光學單元和光電元件
AU2021454491B2 (en) * 2021-07-02 2024-12-05 Ascletis BioScience Co., Ltd Heterocyclic compounds as immunomodulators of pd-l1 interactions
CN119212987A (zh) * 2021-12-16 2024-12-27 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物
CN115010658B (zh) * 2022-05-11 2023-06-27 南方医科大学 一种化合物及其制备方法与应用
WO2024088036A1 (zh) * 2022-10-26 2024-05-02 西安新通药物研究股份有限公司 一种非对称性联苯衍生物及其制备方法与医药用途
JP7873907B2 (ja) * 2022-11-22 2026-06-15 西安新通薬物研究股▲フン▼有限公司 新規二環系pd-l1阻害剤、その製造方法、及び医薬使用
CN116903489B (zh) * 2023-07-14 2025-09-02 北京汉典制药有限公司 三联苯类化合物、其制备方法及其应用
CN121969623A (zh) * 2023-08-01 2026-05-01 艾伊莱布 作为pd-l1抑制剂的新型联苯衍生物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
BR112018077075A2 (pt) * 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
KR102599339B1 (ko) 2016-12-20 2023-11-08 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 화합물
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
US10654815B2 (en) 2016-12-29 2020-05-19 Shenzhen Chipscreen Biosciences Co., Ltd. Urea compound and preparation method and application thereof
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JP7150745B2 (ja) 2017-03-27 2022-10-11 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤としての置換イソキノリン誘導体
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2019120297A1 (zh) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
KR102666727B1 (ko) 2017-12-29 2024-05-21 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도
US11414418B2 (en) 2018-01-23 2022-08-16 Bristol-Myers Squibb Company Compounds useful as immunomodulators
AU2019214089B2 (en) 2018-02-05 2021-02-11 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method therefor and pharmaceutical use thereof
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11578054B2 (en) 2018-03-01 2023-02-14 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN111886219B (zh) 2018-07-11 2023-04-25 上海和誉生物医药科技有限公司 免疫抑制剂及其制备方法和在药学上的应用
CN112384500B (zh) 2018-07-12 2024-05-14 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020015716A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
WO2020015717A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
EP3831823A4 (en) 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
BR112021022659A2 (pt) * 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
KR102841588B1 (ko) * 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물

Similar Documents

Publication Publication Date Title
JP2022531970A5 (enExample)
JP2022536845A5 (enExample)
JP2022551973A5 (enExample)
JP2022551972A5 (enExample)
JP2019527202A5 (enExample)
JP2011510995A5 (enExample)
JP2018158926A5 (enExample)
JP2020528905A5 (enExample)
JP2023512038A5 (enExample)
JP2009513703A5 (enExample)
JP5746172B2 (ja) ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物
KR101258426B1 (ko) 세포 증식과 관련된 질환 치료용 배합물
JP2022551668A5 (enExample)
JP2023515235A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2016510783A5 (enExample)
JP2004514718A5 (enExample)
CN111194214A (zh) 施用sting激动剂的方法
RU2014153800A (ru) Соединения 5-азаиндазола и способы их применения
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
RU2014131378A (ru) Ингибиторы бромдомена
CN109568312A (zh) 用于治疗癌症的化合物
AU2010243213B2 (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
JP2018529739A5 (enExample)
JP2020504716A5 (enExample)